A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

V.F. Corp.'s Q3 fiscal 2025 earnings exceeded expectations, yet shares fell 4% after initial euphoria. Read why I remain ...

It's time -- way past time, actually -- for Amazon to move on from Kirk Herbstreit as part of its NFL Thursday Night Football coverage. 2024 was a rough year for Herbstreit. The criticism for the ...

If there's one thing we didn't expect to find, it's this pair of all-weather hiking boots from The North Face for half off ...

If it’s been more than four hours and your hard-on isn’t going away, you could be suffering from priapism. It’s a serious ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

As we prepare to enter into the Year of the Snake, we take a moment to recognise the unique qualities this zodiac sign ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Let's explore how business leaders can prepare for success amid rising threats despite a formidable landscape.

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.